Ageing, Cellular Senescence and Neurodegenerative Disease
Open accessThe DOI matches its Crossref record; 374 of the 385 references it cites were found in a registry or an index; 63 of the 277 sources its claims cite were checked for support.
Abstract
Ageing is a major risk factor for developing many neurodegenerative diseases. Cellular senescence is a homeostatic biological process that has a key role in driving ageing. There is evidence that senescent cells accumulate in the nervous system with ageing and neurodegenerative disease and may predispose a person to the appearance of a neurodegenerative condition or may aggravate its course. Research into senescence has long been hindered by its variable and cell-type specific features and the lack of a universal marker to unequivocally detect senescent cells. Recent advances in senescence markers and genetically modified animal models have boosted our knowledge on the role of cellular senescence in ageing and age-related disease. The aim now is to fully elucidate its role in neurodegeneration in order to efficiently and safely exploit cellular senescence as a therapeutic target. Here, we review evidence of cellular senescence in neurons and glial cells and we discuss its putative role in Alzheimer’s disease, Parkinson’s disease and multiple sclerosis and we provide, for the first time, evidence of senescence in neurons and glia in multiple sclerosis, using the novel GL13 lipofuscin stain as a marker of cellular senescence.
Overview
CoChat Summary
TL;DR
This review argues that cellular senescence contributes to ageing and neurodegenerative disease, with senescent cells accumulating in the nervous system and potentially influencing disease susceptibility, onset, and progression. It also reports novel GL13 lipofuscin evidence of senescent glia and neurons in secondary progressive multiple sclerosis lesions.
Key findings
- Cellular senescence is a homeostatic response triggered by irreparable DNA damage; senescent cells increase with ageing and are implicated in Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The review states a primary causative role in neurodegeneration is unlikely, but senescence may contribute to susceptibility, age at presentation, and rate of progression.
- Senescence-like features are reported across CNS cell types, including astrocytes, microglia, oligodendrocytes, oligodendrocyte progenitor cells, neurons, and neural stem cells. In aged mice, about 20–80% of mature neurons exhibit a senescence-like phenotype; oligodendrocyte progenitor cells constitute approximately 3–10% of glial cells; brain volume loss may amount to up to 0.4% annually.
- Disease-specific evidence includes elevated p16INK4a mRNA in PD brain, increased SA-β-gal in CSF from PD patients, and elevated SASP-related cytokines in AD and PD. However, a meta-analysis showed no difference in telomere length between PD patients and age-matched controls, and AD telomere findings remain inconclusive.
- Novel MS findings: GL13 lipofuscin histochemistry detected lipofuscin+ glial cells in acute active and chronic active demyelinated white matter lesions from SP-MS cases, sparse cells in chronic inactive lesions, none in normal appearing white matter, and granular lipofuscin deposits in numerous neurons in subpial demyelinated cortical lesions and normal appearing cortex.
Methods
- Narrative review of cellular senescence in ageing and neurodegeneration, focusing on Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.
- For the new MS evidence, the authors used GL13 (SenTraGor) lipofuscin histochemistry as a senescence marker on MS white matter lesions, normal appearing white matter, and cortical lesions; they also cite cuprizone-induced demyelination model data with correlation analysis between senescent glial cell number and demyelination/motor performance.
- No systematic review, meta-analysis, or primary sample size/statistical methods are stated for the MS histochemistry.
Limitations
- Stated: evidence connecting cellular senescence with mechanisms of neurodegeneration remains indirect and further investigation is required.
- Stated: the MS findings merit further quantitative investigation to differentiate ageing effects from MS and to associate senescence extent with other pathological and clinical parameters.
- Stated: no universal specific senescence marker exists and no consensus on optimal marker combination; senescence features are variable and cell-type specific. Evident: as a narrative review, it does not provide systematic search/quality assessment, and the primary MS histochemistry sample details are not reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Lipofuscin accumulation as a marker of cellular senescence in multiple sclerosis lesions. Demyelinated lesions were identified with myelin basic protein (MBP) immunohistochemistry and were staged according to Trapp et al. (1998) [287] as acute active, chronic active or chronic inactive using human leukocyte antigen-DR isotype (HLA-DR) immunohistochemistry on serial sections from paraffin embedded postmortem tissue blocks. Lipofuscin was detected with the GL13 hybrid histochemistry-immunohistochemistry method [58]. Acute active demyelinated white matter lesion with MBP staining showing ongoing perivascular demyelination in subcortical white matter from the parietal lobe of a 73-year-old secondary progressive multiple sclerosis (SP-MS) patient (MS51) (A(i)). Infiltration with HLA-DR+ cells with macrophage morphology throughout the demyelinated parenchyma (HLA DR immunohistochemistry) (A(ii)). Perivascular infiltration with CD8+ lymphocytes (CD8 immunohistochemistry) (A(iii)). GL13 staining in acute active lesions showed lipofuscin+ cells. Although many of them were perivascularly localized, some were not, suggesting that at least some of them maybe glial cells rather than inflammatory cells (A(iv)). Chronic actively demyelinating perivenentricular white matter lesion with a fully demyelinated lesion center (lack of MBP immunoreactivity) from a 74-year-old female MS patient (MS265) (B(i)). Typically, HLA-DR immunohistochemistry of serial sections exhibited a border infiltrated by numerous macrophages whereas the lesion centre is infiltrated by ramified microglia (B(ii)). Few CD8+ lymphocytes are present perivascularly (CD8 immunohistochemistry) (B(iii)). Lipofuscin+ cells with granular staining were found in the macrophage infiltrated lesion border (B(iv)). Chronic inactive subcortical white matter demyelinated lesion (lack of MBP immunoreactivity with a well demarcated border) from the left parietal lobe of a 71-year-old female SP-MS patient (MS33) (C(i)). Ramified microglial morphology throughout the demyelinated lesion area and lesion border (HLA-DR immunohistochemistry) typical of a chronic inactive lesion (C(ii)). Decreased axonal density in the demyelinated lesion seen with 200 KDa neurofilament immunohistochemistry (C(iii)). Numerous parenchymal lipofuscin+ cells in the demyelinated white matter. Lack of HLA-DR+ macrophages from the chronic demyelinated lesion suggests that the lipofuscin+ cells are glial (C(iv)). Subpial cortical demyelination (lack of MBP immunoreactivity extending from the pial surface into the deeper cortical layers from the parietal cortex of a 71-year-old female SP-MS patient (MS33) (D(i)). HLA-DR+ ramified microglia in the demyelinated cortical lesion (D(ii)) and few CD8+ lymphocytes infiltrating the adjacent pia matter (D(iii)). Lipofuscin+ cells mostly with neuronal morphology (inset) throughout the demyelinated cortex (D(iv)). Normal appearing cortex with intact appearing cortical myelin (MBP immunohistochemistry) from the left parietal lobe of a 71-year-old female SP-MS patient (MS33) (E(i)), HLA-DR immunoreactivity revealing quiescent ramified microglia (E(ii)) and normal-appearing axonal staining with 200 kDa neurofilament immunohistochemistry on a serial section (E(iii)). GL13 staining showed numerous lipofuscin+ cells mostly with neuronal morphology (E(iv)). Scale bars represent 500 μm (A(i),A(ii),B(i),B(ii),C(i),C(ii),C(iii),D(i),D(ii),E(i),E(ii)), 50 μm (D(iii),E(iii)) or 25 μm (A(iii),A(iv), B(iii), B(iv), C(iv), D(iv), E(iv)).](https://figures.cochat.ai/paper-figures/6bbbad0f51864a21a639dec131aee479/ageing-cellular-senescence-and-neurodegenerative-disease-figure-1.jpg)
Verification
Claims the paper makes
34 Valid · 2 Not valid · 116 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Age is the strongest predictor for the transition from the relapsing phase of MS, which is primarily inflammatory to the secondary progressive phase of the disease, which is thought to be mainly neurodegenerative [10,11].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 1. Ageing and Neurodegeneration
What the sources say
- Not checked yetcites [10] Trapp B.D. Nave K.-A. Multiple Sclerosis: An Immune or Neurodegenerative Disorder? Annu. Rev. Neurosci. 2008 31 247 269 10.1146/annurev.neuro.30.051606.094313 18558855 source
- Partly supportedcites [11] Scalfari A. Neuhaus A. Daumer M. Ebers G.C. Muraro P.A. Age and disability accumulation in multiple sclerosis Neurology 2011 77 1246 1252 10.1212/WNL.0b013e318230a17d 21917763 PMC3179646 sourceExperimental — accuracy not yet measured
The Age at disease onset section reports that older age at relapsing-remitting onset increases the probability of conversion to secondary progressive MS. The Multiple analysis section finds an age effect independent of early relapse frequency, but does not establish age as the strongest predictor. Page numbers are not available in our copy. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Incidence of Parkinson’s disease (PD), the second most common age-related neurodegenerative condition also increases with age [8,9].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 1. Ageing and Neurodegeneration
What the sources say
- Not checked yetcites [8] Blin P. Dureau-Pournin C. Foubert-Samier A. Grolleau A. Corbillon E. Jové J. Lassalle R. Robinson P. Poutignat N. Droz-Perroteau C. Moore N. Parkinson’s disease incidence and prevalence assessment in France using the national healthcare insurance database Eur. J. Neurol. 2015 22 464 471 10.1111/ene.12592 25389031 source
- Supportedcites [9] Duncan G.W. Khoo T.K. Coleman S.Y. Brayne C. Yarnall A.J. O’Brien J.T. Barker R.A. Burn D.J. The incidence of Parkinson’s disease in the North-East of England Age Ageing 2014 43 257 263 10.1093/ageing/aft091 23880142 source
The Key points section (p. 1 of that block) states outright 'The incidence of PD increases with age', and the Discussion reports that incidence 'peaked in the eighth decade' with 68% of new diagnoses aged over 70, backed by the age- and sex-specific crude rates in Table 2 (rising from 0.4 per 100 000 at 0-39 to 110.0 at 70-79). The Introduction also supports the framing that PD is 'the second most common neurodegenerative disorder after Alzheimer's disease'. The only caveat is the drop-off after 80, which the authors themselves flag as possibly reflecting under-ascertainment rather than a true decline. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another key feature of cellular senescence is the senescence-associated secretory phenotype (SASP), which is dependent on p38MAPK (p38 mitogen-activated protein kinases), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), cGAS(cyclic GMP-AMP synthase)/STING(stimulator of IFN genes), NOTCH and mTORmammalian target of rapamycin) signalling [38,39,40,41,42].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 3. The Senescence Phenotype
What the sources say
- Partly supportedcites [38] Baker D.J. Wijshake T. Tchkonia T. LeBrasseur N.K. Childs B.G. van de Sluis B. Kirkland J.L. van Deursen J.M. Clearance of p16Ink4a -positive senescent cells delays ageing- associated disorders Nature 2012 479 232 236 10.1038/nature10600 22048312 PMC3468323 sourceExperimental — accuracy not yet measured
The paper’s concluding discussion describes the senescence-associated secretory phenotype (SASP) as enabling secretion of growth factors, cytokines and proteases. It does not address whether SASP depends on p38MAPK, NF-κB, cGAS/STING, NOTCH or mTOR signalling (pages unavailable in our copy). (LLM, conf=0.85)
- Not checked yetcites [39] Krenning L. Feringa F.M. Shaltiel I.A. VandenBerg J. Medema R.H. Transient activation of p53 in G2 phase is sufficient to induce senescence Mol. Cell 2014 55 59 72 10.1016/j.molcel.2014.05.007 24910099 source
- Could not verifycites [40] Stein G.H. Drullinger L.F. Soulard A. Dulić V. Differential Roles for Cyclin-Dependent Kinase Inhibitors p21 and p16 in the Mechanisms of Senescence and Differentiation in Human Fibroblasts Mol. Cell. Biol. 1999 19 2109 2117 10.1128/MCB.19.3.2109 10022898 PMC84004 sourceExperimental — accuracy not yet measured
The Results and Discussion describe altered expression of extracellular-matrix-related genes in senescent fibroblasts, but do not address whether the senescence-associated secretory phenotype depends on the listed signalling pathways. Searches for SASP and for p38MAPK, NF-κB, cGAS/STING, NOTCH and mTOR found no passage establishing those dependencies. (LLM, conf=0.76)
- Could not verifycites [41] Sharma V. Gilhotra R. Dhingra D. Gilhotra N. Possible underlying influence of p38MAPK and NF-κB in the diminished anti-anxiety effect of diazepam in stressed mice J. Pharmacol. Sci. 2011 116 257 263 10.1254/jphs.11026FP 21720097 sourceExperimental — accuracy not yet measured
The Discussion addresses a possible p38MAPK–NF-κB relationship in immobilization-stress-induced anxiety in mice, not in cellular senescence. Searches for SASP, cellular senescence, cGAS/STING, NOTCH, and mTOR found no passage linking these pathways to the secretory phenotype. Page numbers were not available in our copy. (LLM, conf=0.78)
- Partly supportedcites [42] Yang H. Wang H. Ren J. Chen Q. Chen Z.J. cGAS is essential for cellular senescence Proc. Natl. Acad. Sci. USA 2017 114 E4612 E4620 10.1073/pnas.1705499114 28533362 PMC5468617 sourceExperimental — accuracy not yet measured
The Results report that cGAS deletion prevented induction of SASP genes after etoposide treatment, and the introductory text describes STING as a downstream component of cGAS signalling. But the paper does not establish that SASP depends on STING; the Discussion also raises STING-independent roles for cGAS. This citation supports the cGAS portion of the cited signalling claim, not its asserted STING dependence. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Altered mitochondrial function appears essential in mediating the senescence phenotype.”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 3. The Senescence Phenotype
What the sources say
- Partly supportedcites [60] Correia-Melo C. Marques F.D. Anderson R. Hewitt G. Hewitt R. Cole J. Carroll B.M. Miwa S. Birch J. Merz A. Mitochondria are required for pro-ageing features of the senescent phenotype EMBO J. 2016 35 724 742 10.15252/embj.201592862 26848154 PMC4818766 sourceExperimental — accuracy not yet measured
The Results report that mitochondrial depletion reduced multiple senescence markers and pro-inflammatory signals. The Discussion describes mitochondria as key to major ageing-promoting features, but says they are less important for proliferation arrest, which persisted after depletion. Thus the paper supports their role in major features, not their being essential to the entire senescence phenotype. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ageing brain has higher background levels of low-grade inflammation primarily in the form of dystrophic microglia and increased levels pro-inflammatory cytokines and other mediators, a state known as inflammaging [100,101,102].”
§ Ageing, Cellular Senescence and Neurodegenerative Disease > 5. Cellular Senescence and Its Putative Role in Neurodegeneration
What the sources say
- Not checked yetcites [100] Streit W.J. Sammons N.W. Kuhns A.J. Sparks D.L. Dystrophic Microglia in the Aging Human Brain Glia 2004 45 208 212 10.1002/glia.10319 14730714 source
- Not checked yetcites [101] Rawji K.S. Mishra M.K. Michaels N.J. Rivest S. Stys P.K. Yong V.W. Immunosenescence of microglia and macrophages: Impact on the ageing central nervous system Brain 2016 139 653 661 10.1093/brain/awv395 26912633 PMC5839598 source
- Partly supportedcites [102] Olivieri F. Prattichizzo F. Grillari J. Balistreri C.R. Cellular Senescence and Inflammaging in Age-Related Diseases Med. Inflamm. 2018 2018 1 6 10.1155/2018/9076485 29849499 PMC5932453 sourceExperimental — accuracy not yet measured
In the main text (page unavailable), the paper defines inflammaging as chronic, systemic, low-grade inflammation and describes secretion of pro-inflammatory mediators. It also mentions a link between inflammaging and neurodegenerative diseases, but does not describe higher background inflammation specifically in the ageing brain or identify dystrophic microglia as its primary form. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
122 more claims · 25 with their cited sources checked
Create a free account to see all 185 claims and to verify the 214 references still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 49
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Age‐related alterations in the brain microenvironment gradually led to increased BBB permeability and leakiness, neuronal degeneration, production of reactive oxygen species (ROS) and inflammation. 54 , 55 , 56”
From Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review (2023) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The senescence stress response allows damaged cells to survive by upregulating senescent cell anti-apoptotic pathways (SCAPs)10 and causes inflammation through their senescence-associated secretory phenotype (SASP)11,12.”
From Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“TMAO is an amine oxide product of the bacterial metabolism that has been implicated in oxidative stress enhancement, BBB disruption, mitochondria dysfunction, brain aging and neurodegeneration [105,106,107]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“Through dysregulation of p38 mitogen-activated protein kinases (p38MAPK), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), NOTCH, and mammalian target of rapamycin (mTOR) signaling, senescent cells can develop a senescence-associated secretory phenotype (SASP) (22, 23).”
From Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial (2022) · cites this paper as [22]
In the citing paper
“Senescence of the central nervous system (CNS) drives many neurodegenerative diseases [55], including Alzheimer’s disease (AD), Parkinson’s disease (PD) and other types of dementia (Table 1).”
From Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases (2020) · cites this paper as [55]
Citations
Cites
1 retracted
Items 201–374 of 374
The role of inflammation in age-related disease
Howcroft, T. K., Campisi, J., Louis, G. B., Smith, M. T., Wise, B., Wyss-Coray, T., Augustine, A. D., McElhaney, J. E., Kohanski, R., & Sierra, F. (2013) · Aging · doi:10.18632/aging.100531 · Cited by 239 · cited 3×
“However, several lines of evidence indicate that cellular senescence also contributes to the loss of function associated with ageing and age-related disease [20].”
BackgroundRapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
Arriola Apelo, S. I., & Lamming, D. W. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw090 · Cited by 239
Dursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., Atasoy, İ. L., Alaylıoğlu, M., Araz, Ö. S., Önal, B., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.014 · Cited by 237 · cited 1×
“IL-1β levels have been reported to be elevated in the CSF [218], serum [222] and dopaminergic regions of the striatum from patients with PD compared to controls [253].”
ResultLindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Wiley, C. D., Flynn, J. M., Morrissey, C., Lebofsky, R., Shuga, J., Dong, X., Unger, M. A., Vijg, J., Melov, S., & Campisi, J. (2017) · Aging Cell · doi:10.1111/acel.12632 · Cited by 234 · cited 2×
“Nevertheless, besides telomere shortening, there are many more triggers of cellular senescence including aberrant oncogene activation (oncogene-induced senescence-OIS) [22], stress-induced (stress-induced premature senescence-SIPS) due to oxidative stress [23], ionizing radiation [24], DNA-damaging chemotherapy [25],…”
BackgroundGlucocorticoids suppress selected components of the senescence‐associated secretory phenotype
Laberge, R., Zhou, L., Sarantos, M. R., Rodier, F., Freund, A., de Keizer, P. L. J., Liu, S., Demaria, M., Cong, Y., Kapahi, P., et al. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00818.x · Cited by 229 · cited 1×
“Cortisol and corticosterone Prevented senescence of human fibroblasts in vitro Inflammation, allergy senomorphic [362]”
BackgroundMeta-analysis of Telomere Length in Alzheimer’s Disease
Forero, D. A., González-Giraldo, Y., López-Quintero, C., Castro-Vega, L. J., Barreto, G. E., & Perry, G. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw053 · Cited by 229
Why do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228
Lack of Replicative Senescence in Cultured Rat Oligodendrocyte Precursor Cells
Tang, D. G., Tokumoto, Y. M., Apperly, J. A., Lloyd, A. C., & Raff, M. C. (2001) · Science · doi:10.1126/science.1056780 · Cited by 228 · cited 1×
“Although OPCs do not undergo replicative senescence [166], there is in vitro evidence that under some circumstances they enter a senescence-like state.”
BackgroundMechanisms of Mitochondrial Dysfunction in Alzheimer’s Disease
Cadonic, C., Sabbir, M. G., & Albensi, B. C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9515-5 · Cited by 226
Neuropathologic basis of white matter hyperintensity accumulation with advanced age
Erten-Lyons, D., Woltjer, R., Kaye, J., Mattek, N., Dodge, H. H., Green, S., Tran, H., Howieson, D. B., Wild, K., & Silbert, L. C. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a43e45 · Cited by 225
Small-Molecule Allosteric Activators of Sirtuins
Sinclair, D. A., & Guarente, L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134657 · Cited by 223
Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222 · cited 1×
“, 50–60% of nigral neurons are already lost at PD diagnosis [302], a great effort is being made to diagnose neurodegenerative disease presymptomatically using different biomarkers.”
Backgroundβ-Amyloid precursor polypeptide in SAMP8 mice affects learning and memory
Morley, J. E., Kumar, V. B., Bernardo, A. E., Farr, S. A., Uezu, K., Tumosa, N., & Flood, J. F. (2000) · Peptides · doi:10.1016/s0196-9781(00)00342-9 · Cited by 221
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias
Tarkowski, E., Liljeroth, A.-M., Minthon, L., Tarkowski, A., Wallin, A., & Blennow, K. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00088-1 · Cited by 219
P38 MAP kinase is activated at early stages in Alzheimer's disease brain
Sun, A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00180-8 · Cited by 219
Huell, M., Strauss, S., Volk, B., Berger, M., & Bauer, J. (1995) · Acta Neuropathologica · doi:10.1007/bf00571510 · Cited by 214
Brain interleukin-1 beta in Alzheimer's disease and vascular dementia.
Cacabelos, R., Alvarez, X. A., Fernández‐Novoa, L., Franco, A., Mangues, R., Pellicer, À., & Nishimura, T. (1994) · PubMed · Cited by 212
Tasselli, L., Xi, Y., Zheng, W., Tennen, R. I., Odrowaz, Z., Simeoni, F., Li, W., & Chua, K. F. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3202 · Cited by 211
Chen, H., Ruiz, P. D., McKimpson, W. M., Novikov, L., Kitsis, R. N., & Gamble, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.011 · Cited by 205 · cited 1×
“These factors are primarily proinflammatory and act in a paracrine and autocrine manner [44,45], although immunosuppressive mediators have also been identified as part of SASP [46,47].”
BackgroundLim, H., Park, H., & Kim, H. P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.013 · Cited by 205
Stress-induced senescence in human and rodent astrocytes
Bitto, A., Sell, C., Crowe, E., Lorenzini, A., Malaguti, M., Hrelia, S., & Torres, C. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.06.021 · Cited by 204
Autophagy in Alzheimer’s disease
Zare-shahabadi, A., Masliah, E., Johnson, G. V. W., & Rezaei, N. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0076 · Cited by 204 · cited 1×
“This is supported by a number of studies reporting dysregulation in many autophagic/lysosomal pathways in the context of AD [234,235], while the vast majority of AD-associated genes appears to be related to these same pathways [232].”
BackgroundWatson, C. T., Roussos, P., Garg, P., Ho, D. J., Azam, N., Katsel, P. L., Haroutunian, V., & Sharp, A. J. (2016) · Genome Medicine · doi:10.1186/s13073-015-0258-8 · Cited by 201
Cellular Senescence and Inflammaging in Age-Related Diseases
Olivieri, F., Prattichizzo, F., Grillari, J., & Balistreri, C. R. (2018) · Mediators of Inflammation · doi:10.1155/2018/9076485 · Cited by 200
Review: Mitochondria and disease progression in multiple sclerosis
Mahad, D., Lassmann, H., & Turnbull, D. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00987.x · Cited by 193
Transient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence
Krenning, L., Feringa, F. M., Shaltiel, I. A., van den Berg, J., & Medema, R. H. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.007 · Cited by 193 · cited 2×
“p16INK4A mediates permanent cells cycle arrest by inhibiting CDK4 and CDK6, which leads to RB hypophosphorylation and blocks entry to S phase [39,40].”
BackgroundDNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age
Kim, H., Chang, J., Shao, L., Han, L., Iyer, S., Manolagas, S. C., O'Brien, C. A., Jilka, R. L., Zhou, D., & Almeida, M. (2017) · Aging Cell · doi:10.1111/acel.12597 · Cited by 192
Webley, K., Bond, J. A., Jones, C. J., Blaydes, J. P., Craig, A., Hupp, T., & Wynford-Thomas, D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2803-2808.2000 · Cited by 192
Substantial Archaeocortical Atrophy and Neuronal Loss in Multiple Sclerosis
Papadopoulos, D., Dukes, S., Patel, R., Nicholas, R., Vora, A., & Reynolds, R. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00177.x · Cited by 192
Self-citationCytokine Gene Expression as a Function of the Clinical Progression of Alzheimer Disease Dementia
Luterman, J. D., Haroutunian, V., Yemul, S., Ho, L., Purohit, D., Aisen, P. S., Mohs, R., & Pasinetti, G. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.8.1153 · Cited by 192
Loss of Bif-1 Suppresses Bax/Bak Conformational Change and Mitochondrial Apoptosis
Takahashi, Y., Karbowski, M., Yamaguchi, H., Kazi, A., Wu, J., Sebti, S. M., Youle, R. J., & Wang, H.-G. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9369-9382.2005 · Cited by 190
The Ubiquitin-Proteasome System and the Autophagic-Lysosomal System in Alzheimer Disease
Ihara, Y., Morishima-Kawashima, M., & Nixon, R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006361 · Cited by 190 · cited 2×
“This is supported by a number of studies reporting dysregulation in many autophagic/lysosomal pathways in the context of AD [234,235], while the vast majority of AD-associated genes appears to be related to these same pathways [232].”
BackgroundResultGezen-Ak, D., Dursun, E., Hanağası, H., Bilgiç, B., Lohman, E., Araz, Ö. S., Atasoy, İ. L., Alaylıoğlu, M., Önal, B., Gürvit, H., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130497 · Cited by 188
Adhami, V. M., Syed, D. N., Khan, N., & Mukhtar, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.012 · Cited by 186
Changes of p53 in the Brains of Patients with Alzheimer's Disease
Kitamura, Y., Shimohama, S., Kamoshima, W., Matsuoka, Y., Nomura, Y., & Taniguchi, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6301 · Cited by 185
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
Samaraweera, L., Adomako, A., Rodriguez-Gabin, A., & McDaid, H. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-01964-1 · Cited by 183
Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180
Telomere Shortening in Neural Stem Cells Disrupts Neuronal Differentiation and Neuritogenesis
Ferrón, S. R., Marqués-Torrejón, M. Á., Mira, H., Flores, I., Taylor, K., Blasco, M. A., & Fariñas, I. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3836-09.2009 · Cited by 179 · cited 1×
“NSCs exhibit features of cellular senescence such as telomere shortening, and ROS production with ageing [181,182].”
BackgroundReactive astrocytes in Alzheimer’s disease: A double-edged sword
Chun, H., & Lee, C. J. (2018) · Neuroscience Research · doi:10.1016/j.neures.2017.11.012 · Cited by 176 · cited 1×
“Astrocytes are key players in the initiation and progression of the disease and can have both beneficial and detrimental effects, depending on different factors [240].”
BackgroundThe response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS
Reynolds, R., Dawson, M., Papadopoulos, D., Polito, A., di Bello, I. C., Pham-Dinh, D., & Levine, J. (2002) · Journal of Neurocytology · doi:10.1023/a:1025747832215 · Cited by 175 · cited 2×
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
BackgroundSelf-citationScalzo, P., Kümmer, A., Cardoso, F., & Teixeira, A. L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.062 · Cited by 175
Wnt4/β−Catenin Signaling in Medullary Kidney Myofibroblasts
DiRocco, D. P., Kobayashi, A., Taketo, M. M., McMahon, A. P., & Humphreys, B. D. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050512 · Cited by 173
SIRT1 suppresses the senescence-associated secretory phenotype through epigenetic gene regulation
Hayakawa, T., Iwai, M., Aoki, S., Takimoto, K., Maruyama, M., Maruyama, W., & Motoyama, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116480 · Cited by 170
The Signaling Pathways Involved in Chondrocyte Differentiation and Hypertrophic Differentiation
Li, J., & Dong, S. (2016) · Stem Cells International · doi:10.1155/2016/2470351 · Cited by 170
Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes
Myung, N.-H., Zhu, X., Kruman, I. I., Castellani, R. J., Petersen, R. B., Siedlak, S. L., Perry, G., Smith, M. A., & Lee, H.-G. (2008) · AGE · doi:10.1007/s11357-008-9050-7 · Cited by 170 · cited 1×
“Furthermore, increased levels of γH2AX have been found in astrocytes from AD hippocampal samples [241].”
BackgroundCipriani, S., Ferrer, I., Aronica, E., Kovacs, G. G., Verney, C., Nardelli, J., Khung, S., Delezoide, A.-L., Milenkovic, I., Rasika, S., et al. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy096 · Cited by 169 · cited 1×
“Ageing has been shown to significantly reduce adult hippocampal neurogenesis [109].”
BackgroundCellular senescence induced by CD158d reprograms natural killer cells to promote vascular remodeling
Rajagopalan, S., & Long, E. O. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208248109 · Cited by 168
Astrocytes aged in vitro show a decreased neuroprotective capacity
Pertusa, M., García‐Matas, S., Rodríguez‐Farré, E., Sanfeliu, C., & Cristòfol, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04369.x · Cited by 168 · cited 1×
“It has been reported that cultured rat astrocytes show characteristics of senescence, such as increased SA-β-gal staining, robust ROS production and decreased mitochondrial activity, resulting in the loss of their ability to maintain neurons and therefore exerting detrimental effects in the aging brain [137,138].”
BackgroundKuan, Y.-C., Huang, K.-W., Lin, C.-L., Hu, C.-J., & Kao, C.-H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.002 · Cited by 168 · cited 1×
“For example, although some epidemiological studies supported a protective role for metformin, which crosses the BBB, in preventing cognitive decline in individuals with type 2 diabetes [304], another 12-year cohort study in patients with type 2 diabetes showed a two-fold increase in the risk of AD and PD in those who…”
ResultBoth telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescence
Nakamura, A. J., Chiang, Y. J., Hathcock, K. S., Horikawa, I., Sedelnikova, O. A., Hodes, R. J., & Bonner, W. M. (2008) · Epigenetics & Chromatin · doi:10.1186/1756-8935-1-6 · Cited by 168
Quercetin: A Pleiotropic Kinase Inhibitor Against Cancer
Russo, G. L., Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S., Iannitti, R., & Palumbo, R. (2014) · Cancer Treatment and Research · doi:10.1007/978-3-642-38007-5_11 · Cited by 167
Human neural stem cells alleviate Alzheimer-like pathology in a mouse model
Lee, I.-S., Jung, K., Kim, I.-S., Lee, H., Kim, M., Yun, S., Hwang, K., Shin, J. E., & Park, K. I. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0035-6 · Cited by 167 · cited 1×
“Although the role of adult neurogenesis in AD remains contentious, studies from animal models indicate that ablation of adult neurogenesis exacerbates memory deficits and upregulates hyperphosphorylated tau [111], whereas implantation of human neural stem cells alleviates memory deficits and AD pathology [112].”
BackgroundProgressive telomere shortening occurs in cultured rat microglia, but not astrocytes
Flanary, B. E., & Streit, W. J. (2004) · Glia · doi:10.1002/glia.10301 · Cited by 167 · cited 2×
“Cultured rat microglial cells have been reported to undergo replicative senescence due to telomere shortening [153] and the same finding was later reported for microglial cells from AD patients [154].”
BackgroundResultPei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3107 · Cited by 165
Tiribuzi, R., Crispoltoni, L., Porcellati, S., Di Lullo, M., Florenzano, F., Pirro, M., Bagaglia, F., Kawarai, T., Zampolini, M., Orlacchio, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.003 · Cited by 162 · cited 1×
“However, SA-β-Gal was significantly decreased in monocytes and lymphocytes from AD patients compared to controls, a finding attributed to the up-regulation of miR-128 [186].”
Mitochondria: Are they causal players in cellular senescence?
Correia-Melo, C., & Passos, J. F. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.05.017 · Cited by 160
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160 · cited 1×
“From our limited experience so far it is evident that, in most cases, the senescence-modifying action is not universal, but rather cell-type dependent, which greatly complicates the therapeutic landscape [303].”
BackgroundSelf-citationTelomere shortening in neurological disorders: an abundance of unanswered questions
Eitan, E., Hutchison, E. R., & Mattson, M. P. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.02.010 · Cited by 158 · cited 1×
“The evidence concerning telomere length in PD remain inconclusive, [246] with a number of different studies reporting contradictory results [265–270].”
ResultMicroglia change from a reactive to an age-like phenotype with the time in culture
Caldeira, C., Oliveira, A. F., Cunha, C., Vaz, A. R., Falcão, A. S., Fernandes, A., & Brites, D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00152 · Cited by 156 · cited 1×
“A recent study reported that in vitro aged microglia from rats [244], after treatment with Aβ oligomers acquire a senescent phenotype, characterized by increased levels of SA-β-gal, IL-1β, TNF-α and MMP-2 [245].”
BackgroundEpigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
Ferrón, S., Mira, H., Franco, S., Cano-Jaimez, M., Bellmunt, E., Ramírez, C., Fariñas, I., & Blasco, M. A. (2004) · Development · doi:10.1242/dev.01215 · Cited by 152 · cited 1×
“NSCs may undergo senescence in vitro in response to various stressors [178].”
BackgroundDasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia
Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0677-x · Cited by 151
He, N., Jin, W.-L., Lok, K.-H., Wang, Y., Yin, M., & Wang, Z.-J. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.437 · Cited by 151 · cited 4×
“These senescent NSCs have also been observed in the dentate gyrus of the APP/PS1 transgenic mouse AD model [179].”
BackgroundResultInfluentialAntioxidant properties of the flavonoid fisetin: An updated review of in vivo and in vitro studies
Farsad-Naeimi, A., & Alizadeh, M. (2017) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2017.10.003 · Cited by 149
Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, Fisetin
Lu, H., Chang, D. J., Baratte, B., Meijer, L., & Schulze-Gahmen, U. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049353p · Cited by 147
Stamatovic, S. M., Martinez-Revollar, G., Hu, A., Choi, J., Keep, R. F., & Andjelkovic, A. V. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.006 · Cited by 146
WEBB, M. R., & EBELER, S. E. (2004) · Biochemical Journal · doi:10.1042/bj20040474 · Cited by 145
Kirkwood, T. B. L., Feder, M., Finch, C. E., Franceschi, C., Globerson, A., Klingenberg, C. P., LaMarco, K., Omholt, S., & Westendorp, R. G. J. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.09.008 · Cited by 144 · cited 1×
“Accumulating damage is thought to occur inherently in a random manner, which explains the great diversity in ageing phenotypes, even in monozygotic twins [13].”
BackgroundHollands, C., Tobin, M. K., Hsu, M., Musaraca, K., Yu, T.-S., Mishra, R., Kernie, S. G., & Lazarov, O. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0207-7 · Cited by 143
Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities
Brickman, A. M. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0415-7 · Cited by 141
Hubbard, G. P., Stevens, J. M., Cicmil, M., Sage, T., Jordan, P. A., Williams, C. M., Lovegrove, J. A., & Gibbins, J. M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00212.x · Cited by 137
Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease
Arendt, T., Holzer, M., & Gärtner, U. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050104 · Cited by 137 · cited 1×
“However, the evidence remains inconclusive, as a number of studies have reported increased levels in the brains of AD patients compared to controls [192,193], while others have found no significant differences [194].”
BackgroundRelationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged
Rubenstein, E. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09234-9 · Cited by 136 · cited 1×
“Although senescence has not been studied in the cellular components of the choroid plexus, it is known to undergo several age and disease-related structural and functional alterations [131,132].”
BackgroundPardo, G., & Jones, D. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8594-9 · Cited by 135
Oligodendrocytes and Alzheimer's disease
Cai, Z., & Xiao, M. (2016) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1025778 · Cited by 133 · cited 1×
“Oligodendrocytes and oligodendrocyte precursor cells (OPCs) dysfunction, as well as myelin breakdown have been suggested to also play an important role in the pathogenesis and progression of AD, although the exact mechanisms remain unclear [164,171].”
BackgroundGene expression profiling of replicative and induced senescence
Purcell, M., Kruger, A., & Tainsky, M. A. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973327 · Cited by 132
Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin
Syed, D., Adhami, V., Khan, M., & Mukhtar, H. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990129 · Cited by 129
Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain
Yoshiyama, Y., Asahina, M., & Hattori, T. (2000) · Acta Neuropathologica · doi:10.1007/pl00007428 · Cited by 128
Cerebrovascular disease, beta-amyloid, and cognition in aging
Marchant, N. L., Reed, B. R., DeCarli, C. S., Madison, C. M., Weiner, M. W., Chui, H. C., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.001 · Cited by 127 · cited 1×
“Interestingly, the Aβ plaques may be found in 35% of cognitively healthy individuals above the age of 60 [290] and the Aβ load, which has been our main target, correlates better with age than disease severity in AD [291–293], casting doubt on the amyloid hypothesis.”
Transport across the choroid plexus epithelium
Praetorius, J., & Damkier, H. H. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00041.2017 · Cited by 125
Poulsen, R. C., Watts, A. C., Murphy, R. J., Snelling, S. J., Carr, A. J., & Hulley, P. A. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203146 · Cited by 123
Role of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death
Choi, D.-H., Kim, Y.-J., Kim, Y.-G., Joh, T. H., Beal, M. F., & Kim, Y.-S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.222430 · Cited by 123 · cited 1×
“Elevated TNF-α levels have been reported in the striatum and the CSF of PD patients compared to controls [258], while MMP-3 was found to co-localize with α-synuclein in the Lewy bodies in PD patients’ brains [259].”
Activation of Lung p53 by Nutlin-3a Prevents and Reverses Experimental Pulmonary Hypertension
Mouraret, N., Marcos, E., Abid, S., Gary-Bobo, G., Saker, M., Houssaini, A., Dubois-Rande, J.-L., Boyer, L., Boczkowski, J., Derumeaux, G., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002434 · Cited by 123 · cited 1×
“, using corticosteroids [368], beta-interferons [370] or DNA-damaging chemotherapeutics in MS, practices that may prove detrimental in the long run.”
BackgroundThe epigenetic landscape of Alzheimer's disease
Lord, J., & Cruchaga, C. (2014) · Nature Neuroscience · doi:10.1038/nn.3792 · Cited by 122
From cellular senescence to Alzheimer’s disease: The role of telomere shortening
Boccardi, V., Pelini, L., Ercolani, S., Ruggiero, C., & Mecocci, P. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.04.003 · Cited by 121
Expression Patterns of Retinoblastoma Protein in Parkinson Disease
Jordan-Sciutto, K. L., Dorsey, R., Chalovich, E. M., Hammond, R. R., & Achim, C. L. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.1.68 · Cited by 121
Turenne, G. A., Paul, P., Laflair, L., & Price, B. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204665 · Cited by 120 · cited 1×
“When the cell’s repair mechanisms become overwhelmed, the activated DDR elicits cellular senescence via phosphorylation of p53 [33].”
BackgroundHow fisetin reduces the impact of age and disease on CNS function
Maher, P. (2015) · Frontiers in Bioscience · doi:10.2741/s425 · Cited by 119
Cenini, G., Sultana, R., Memo, M., & Butterfield, D. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00163.x · Cited by 117
Key Aging-Associated Alterations in Primary Microglia Response to Beta-Amyloid Stimulation
Caldeira, C., Cunha, C., Vaz, A. R., Falcão, A. S., Barateiro, A., Seixas, E., Fernandes, A., & Brites, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00277 · Cited by 117 · cited 1×
“A recent study reported that in vitro aged microglia from rats [244], after treatment with Aβ oligomers acquire a senescent phenotype, characterized by increased levels of SA-β-gal, IL-1β, TNF-α and MMP-2 [245].”
BackgroundSystemic DNA damage responses in aging and diseases
Ribezzo, F., Shiloh, Y., & Schumacher, B. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.12.005 · Cited by 116 · cited 1×
“Senescent cells may sustain a proinflammatory milieu, which can be damaging for neighboring cells or “contaminating” in the sense of converting neighboring cells to senescent ones in a paracrine manner [44,94,95].”
BackgroundPapadopoulos, D., Pham-Dinh, D., & Reynolds, R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.033 · Cited by 115
Self-citationGörg, B., Karababa, A., Shafigullina, A., Bidmon, H. J., & Häussinger, D. (2015) · Glia · doi:10.1002/glia.22731 · Cited by 115 · cited 1×
“Ammonia has also been shown to trigger cellular senescence in cultured rat astrocytes, mediated by ROS and p38MAPK activation leading to growth arrest and elevated SA-β-gal and p21 levels [144].”
BackgroundNeuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease
Kaur, K., Gill, J. S., Bansal, P. K., & Deshmukh, R. R. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3251 · Cited by 114
Cellular Senescence - its role in cancer and the response to ionizing radiation
Sabin, R. J., & Anderson, R. M. (2011) · Genome Integrity · doi:10.1186/2041-9414-2-7 · Cited by 113 · cited 1×
“Nevertheless, besides telomere shortening, there are many more triggers of cellular senescence including aberrant oncogene activation (oncogene-induced senescence-OIS) [22], stress-induced (stress-induced premature senescence-SIPS) due to oxidative stress [23], ionizing radiation [24], DNA-damaging chemotherapy [25],…”
BackgroundHorstmann, S., Budig, L., Gardner, H., Koziol, J., Deuschle, M., Schilling, C., & Wagner, S. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210000827 · Cited by 110
Bose, R., Moors, M., Tofighi, R., Cascante, A., Hermanson, O., & Ceccatelli, S. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.60 · Cited by 110 · cited 1×
“NSCs exhibit features of cellular senescence such as telomere shortening, and ROS production with ageing [181,182].”
BackgroundChanges in the Transcriptome of Human Astrocytes Accompanying Oxidative Stress-Induced Senescence
Crowe, E. P., Tuzer, F., Gregory, B. D., Donahue, G., Gosai, S. J., Cohen, J., Leung, Y. Y., Yetkin, E., Nativio, R., Wang, L.-S., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00208 · Cited by 110 · cited 1×
“A recent study by Crowe et al. (2016) reported that oxidative stress-induced senescence can cause several transcriptomic changes on human astrocytes.”
BackgroundIntegrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, V. G., Pefani, D., Pateras, I. S., & Trougakos, I. P. (2018) · The Journal of Pathology · doi:10.1002/path.5097 · Cited by 108
Self-citationImplications of time-series gene expression profiles of replicative senescence.
Kim, Y., Byun, H., Jee, B. A., Cho, H., Seo, Y., Kim, Y., Park, M. H., Chung, H., Woo, H. G., & Yoon, G. (2013) · Aging Cell · doi:10.1111/acel.12087 · Cited by 106
Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease
Plotegher, N., & Duchen, M. R. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00110 · Cited by 106
Oligodendroglia Are Particularly Vulnerable to Oxidative Damage after Neurotrauma In Vivo
Giacci, M. K., Bartlett, C. A., Smith, N. M., Iyer, K. S., Toomey, L. M., Jiang, H., Guagliardo, P., Kilburn, M. R., & Fitzgerald, M. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1898-17.2018 · Cited by 105
Borkham-Kamphorst, E., Schaffrath, C., Van de Leur, E., Haas, U., Tihaa, L., Meurer, S. K., Nevzorova, Y. A., Liedtke, C., & Weiskirchen, R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.01.023 · Cited by 105
Lüth, H. J., Holzer, M., Gertz, H.-J., & Arendt, T. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02178-2 · Cited by 105
van Dijk, K. D., Persichetti, E., Chiasserini, D., Eusebi, P., Beccari, T., Calabresi, P., Berendse, H. W., Parnetti, L., & van de Berg, W. D. J. (2013) · Movement Disorders · doi:10.1002/mds.25495 · Cited by 101 · cited 1×
“Increased levels of SA-β-gal have also been found in the CSF from PD patients compared to healthy controls [252].”
BackgroundThe neuronal cell cycle as a mechanism of pathogenesis in Alzheimer's disease
Currais, A., Hortobágyi, T., & Soriano, S. (2009) · Aging · doi:10.18632/aging.100045 · Cited by 101
Silva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099897 · Cited by 99 · cited 1×
“Moreover, elevated phosphorylated histone γH2AX (H2A histone family member X) levels have been reported in the hippocampus and lymphocytes from AD patients, indicating an active DNA damage response [230,231].”
BackgroundInterleukin-6 Serum Levels in Patients with Parkinson’s Disease
Hofmann, K. W., Schuh, A. F. S., Saute, J., Townsend, R., Fricke, D., Leke, R., Souza, D. O., Portela, L. V., Chaves, M. L. F., & Rieder, C. R. M. (2009) · Neurochemical Research · doi:10.1007/s11064-009-9921-z · Cited by 98 · cited 1×
“Increased levels of IL-6 in PD patients’ serum have been reported in a number of studies [254–256], while IL-6 levels have also been associated with disease severity [257].”
BackgroundBrain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease
Leake, A., Morris, C. M., & Whateley, J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01418-x · Cited by 95
Kujuro, Y., Suzuki, N., & Kondo, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911446107 · Cited by 94 · cited 9×
“Evidence of oxidative DNA damage and upregulated SA-β-Gal suggest that oligodendrocytes may undergo stress-associated cellular senescence in ageing individuals [160].”
BackgroundInfluentialExpression of apoptosis related proteins in brains of patients with Alzheimer's disease
Engidawork, E., Gulesserian, T., Seidl, R., Cairns, N., & Lubec, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01618-4 · Cited by 91 · cited 1×
“However, the evidence remains inconclusive, as a number of studies have reported increased levels in the brains of AD patients compared to controls [192,193], while others have found no significant differences [194].”
BackgroundOtt, B. R., Jones, R. N., Daiello, L. A., de la Monte, S. M., Stopa, E. G., Johanson, C. E., Denby, C., & Grammas, P. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00245 · Cited by 91
ATF6α regulates morphological changes associated with senescence in human fibroblasts
Druelle, C., Drullion, C., Deslé, J., Martin, N., Saas, L., Cormenier, J., Malaquin, N., Huot, L., Slomianny, C., Bouali, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11505 · Cited by 87
Age-related neurodegenerative disease research needs aging models
Johnson, I. P. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00168 · Cited by 85
Oxidative Glial Cell Damage Associated with White Matter Lesions in the Aging Human Brain
Al‐Mashhadi, S., Simpson, J. E., Heath, P. R., Dickman, M., Forster, G., Matthews, F. E., Brayne, C., Ince, P. G., Wharton, S. B., & Medical Research Council Cognitive Function and Ageing Study (2015) · Brain Pathology · doi:10.1111/bpa.12216 · Cited by 85 · cited 1×
“Evidence of oxidative DNA damage and upregulated SA-β-Gal suggest that oligodendrocytes may undergo stress-associated cellular senescence in ageing individuals [160].”
BackgroundMansour, H., Chamberlain, C. G., Weible II, M. W., Hughes, S., Chu, Y., & Chan‐Ling, T. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00402.x · Cited by 84 · cited 1×
“It has been reported that cultured rat astrocytes show characteristics of senescence, such as increased SA-β-gal staining, robust ROS production and decreased mitochondrial activity, resulting in the loss of their ability to maintain neurons and therefore exerting detrimental effects in the aging brain [137,138].”
BackgroundA Percentage Analysis of the Telomere Length in Parkinson's Disease Patients
Guan, J. Z., Maeda, T., Sugano, M., Oyama, J.-I., Higuchi, Y., Suzuki, T., & Makino, N. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.5.467 · Cited by 83
Suppression of replicative senescence by rapamycin in rodent embryonic cells
Pospelova, T. V., Leontieva, O. V., Bykova, T. V., Zubova, S. G., Pospelov, V. A., & Blagosklonny, M. V. (2012) · Cell Cycle · doi:10.4161/cc.20882 · Cited by 83
Loss of MECP2 Leads to Activation of P53 and Neuronal Senescence
Ohashi, M., Korsakova, E., Allen, D., Lee, P., Fu, K., Vargas, B. S., Cinkornpumin, J., Salas, C., Park, J. C., Germanguz, I., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.04.001 · Cited by 80 · cited 1×
“In addition, neurons deriving from reprogrammed fibroblasts from patients with Rett syndrome, a neurodegenerative condition due to a MECP loss of function mutation, exhibit evidence of double strand DNA damage and p53-mediated SASP, providing in vitro evidence of a link between cellular senescence and neurodegenerativ…”
BackgroundEvans, R., Wyllie, F. S., Wynford‐Thomas, D., Kipling, D., & Jones, C. J. (2003) · PubMed · Cited by 79
Repeated Lipopolysaccharide Stimulation Induces Cellular Senescence in BV2 Cells
Yu, H.-M., Zhao, Y.-M., Luo, X.-G., Feng, Y., Ren, Y., Shang, H., He, Z.-Y., Luo, X.-M., Chen, S.-D., & Wang, X.-Y. (2012) · Neuroimmunomodulation · doi:10.1159/000330254 · Cited by 76 · cited 4×
“Chromatic alterations such as senescence-associated heterochromatin formation (SAHF) may accompany cellular senescence in some settings with deactivation of proliferation-related genes [70–73].”
BackgroundInfluentialDysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease
Pitcairn, C., Wani, W. Y., & Mazzulli, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.008 · Cited by 75
Blin, P., Dureau‐Pournin, C., Foubert‐Samier, A., Grolleau, A., Corbillon, E., Jové, J., Lassalle, R., Robinson, P., Poutignat, N., Droz‐Perroteau, C., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12592 · Cited by 74 · cited 1×
“Incidence of Parkinson’s disease (PD), the second most common age-related neurodegenerative condition also increases with age [8,9].”
BackgroundPeripheral expression of MAPK pathways in Alzheimer’s and Parkinson’s diseases
Wang, S., Zhang, C., Sheng, X., Zhang, X., Wang, B., & Zhang, G. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.08.017 · Cited by 72 · cited 1×
“Since p38MAPK is a major regulator of SASP [209], it is not surprising that a number of key components of SASP appear to be up-regulated in AD [210,211].”
BackgroundImmunomodulatory therapies delay disease progression in multiple sclerosis
Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., D’Onghia, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458512445941 · Cited by 71 · cited 1×
“In line with our hypothesis, currently used immunomodulatory and immunosuppressive treatments are modestly or not effective in the secondary progressive phase of the disease but may delay the onset of the secondary progressive phase when used early in the inflammatory relapsing phase [281], probably due to their effic…”
ResultSIRT1 Regulation of Wakefulness and Senescence-Like Phenotype in Wake Neurons
Panossian, L., Fenik, P., Zhu, Y., Zhan, G., McBurney, M. W., & Veasey, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5166-10.2011 · Cited by 70 · cited 1×
“Nevertheless, neurons from nuclei of the sleep-wake cycle seem to be particularly prone to lipofuscin accumulation with ageing and those lipofuscin positive neurons exhibited poorer dendritic arborization and decreased neurotransmitter production, indicative of functional compromise [175].”
BackgroundTelomere length in Parkinson's disease: A meta-analysis
Forero, D. A., González-Giraldo, Y., López-Quintero, C., Castro-Vega, L. J., Barreto, G. E., & Perry, G. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.01.002 · Cited by 70 · cited 1×
“, incorporating all these studies, showed that there is no difference in telomere length between PD patients and age-matched controls [270].”
BackgroundWatfa, G., Dragonas, C., Brosche, T., Dittrich, R., Sieber, C. C., Alecu, C., Benetos, A., & Nzietchueng, R. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-010-0275-7 · Cited by 70
Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinsons Disease
Rivero-Ríos, P., Madero-Pérez, Fernández, B., & Hilfiker, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030103027 · Cited by 69
Ginsenoside F1 suppresses astrocytic senescence-associated secretory phenotype
Hou, J., Cui, C.-H., Kim, S., Sung, C. K., & Choi, C. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.02.002 · Cited by 69
Plasma membrane microdomains in aging and disease
Ohno‐Iwashita, Y., Shimada, Y., Hayashi, M., & Inomata, M. (2010) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2010.00600.x · Cited by 68
Cormenier, J., Martin, N., Deslé, J., Salazar-Cardozo, C., Pourtier, A., Abbadie, C., & Pluquet, O. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.003 · Cited by 64
Tavana, O., Benjamin, C. L., Puebla-Osorio, N., Sang, M., Ullrich, S. E., Ananthaswamy, H., & Zhu, C. (2010) · Cell Cycle · doi:10.4161/cc.9.16.12688 · Cited by 63 · cited 1×
“Accumulation of intermediate levels of p53 has been reported to favor the expression of anti-apoptotic bcl-2 family proteins [52].”
BackgroundAge-Related Neurodegeneration and Memory Loss in Down Syndrome
Lockrow, J. P., Fortress, A. M., & Granholm, A.-C. E. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/463909 · Cited by 63
Alzheimer’s disease and the autophagic-lysosomal system
Chung, K. M., Hernández, N., Sproul, A. A., & Yu, W. H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.017 · Cited by 63
Advances in Nutrition and Cancer
Zappia, V., Panico, S., Russo, G. L., Budillon, A., & Ragione, F. D. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5 · Cited by 58
The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease
Nagy, Z. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00485.x · Cited by 56
Pitozzi, V., Mocali, A., Laurenzana, A., Giannoni, E., Cifola, I., Battaglia, C., Chiarugi, P., Dolara, P., & Giovannelli, L. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls183 · Cited by 56
Mutant mice with small amounts of BubR1 display accelerated age-related gliosis
Hartman, T. K., Wengenack, T. M., Poduslo, J. F., & van Deursen, J. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.012 · Cited by 54 · cited 1×
“Finally, prematurely aged BUBR1 mutant mice display alterations in gliosis from activated astrocytes, providing in vivo evidence of a link between accelerated cellular senescence and astrocytic dysfunction [151].”
BackgroundMaeda, T., Guan, J. Z., Koyanagi, M., Higuchi, Y., & Makino, N. (2012) · Journal of Neurogenetics · doi:10.3109/01677063.2011.651665 · Cited by 52
Komseli, E.-S., Pateras, I. S., Krejsgaard, T., Stawiski, K., Rizou, S. V., Polyzos, A., Roumelioti, F.-M., Chiourea, M., Mourkioti, I., Paparouna, E., et al. (2018) · BMC Genomics · doi:10.1186/s12864-017-4375-1 · Cited by 51
Self-citationNo Evidence for Shorter Leukocyte Telomere Length in Parkinson's Disease Patients
Eerola, J., Kananen, L., Manninen, K., Hellstrom, O., Tienari, P. J., & Hovatta, I. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq125 · Cited by 47
Wu, M., Ye, H., Shao, C., Zheng, X., Li, Q., Wang, L., Zhao, M., Lu, G., Chen, B., Zhang, J., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00111 · Cited by 45
Barbouti, A., Evangelou, K., Pateras, I. S., Papoudou-Bai, A., Patereli, A., Stefanaki, K., Rontogianni, D., Muñoz-Espín, D., Kanavaros, P., & Gorgoulis, V. G. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2018.02.005 · Cited by 44
Self-citationNie, X., Liang, L., Xi, H., Jiang, S., Jiang, J., Tang, C., Liu, X., Liu, S., Wan, C., Zhao, J., et al. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3084 · Cited by 43 · cited 1×
“The dioxin TCDD can induce premature senescence in rodent astrocytes through activation of the WNT/β-catenin signaling pathway and ROS production and is characterized by increased levels of senescence markers, such as SA-β-gal, p16 and p21 [143].”
BackgroundTiribuzi, R., Orlacchio, A., Crispoltoni, L., Maiotti, M., Zampolini, M., De Angeliz, M., Mecocci, P., Cecchetti, R., Bernardi, G., Datti, A., et al. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-100525 · Cited by 43 · cited 1×
“Increased level of SA-β-Gal was also found in plasma samples from AD patients, compared to controls [184,185].”
ResultCell-Cycle Markers in a Transgenic Mouse Model of Human Tauopathy
Delobel, P., Lavenir, I., Ghetti, B. F., Holzer, M., & Goedert, M. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050540 · Cited by 42
Alzheimer's disease genes and autophagy
Yoon, S.-Y., & Kim, D.-H. (2016) · Brain Research · doi:10.1016/j.brainres.2016.03.018 · Cited by 42
Age-related decline in BubR1 impairs adult hippocampal neurogenesis
Yang, Z., Jun, H., Choi, C.-I., Yoo, K. H., Cho, C. H., Hussaini, S. M. Q., Simmons, A. J., Kim, S., van Deursen, J. M., Baker, D. J., et al. (2017) · Aging Cell · doi:10.1111/acel.12594 · Cited by 40 · cited 2×
“Furthermore, there is evidence from the BUBR1 KO mouse that accelerated cellular senescence impairs adult neurogenesis in vivo [110].”
BackgroundResultA Model for p38MAPK-Induced Astrocyte Senescence
Mombach, J. C. M., Vendrusculo, B., & Bugs, C. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125217 · Cited by 38
Tan, M., Wang, S., Song, J., & Jia, J. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.093 · Cited by 38 · cited 1×
“Interesting are also the results from AD and tauopathy mouse models [195,196], as well as from studies of peripheral blood lymphocytes and monocytes of AD patients [197,198].”
ResultThe incidence of Parkinson's disease in the North-East of England
Duncan, G. W., Khoo, T. K., Coleman, S. Y., Brayne, C., Yarnall, A. J., O'Brien, J. T., Barker, R. A., & Burn, D. J. (2014) · Age and Ageing · doi:10.1093/ageing/aft091 · Cited by 32 · cited 1×
“Incidence of Parkinson’s disease (PD), the second most common age-related neurodegenerative condition also increases with age [8,9].”
BackgroundDegerman, S., Domellöf, M., Landfors, M., Linder, J., Lundin, M., Haraldsson, S., Elgh, E., Roos, G., & Forsgren, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113387 · Cited by 32
Bialopiotrowicz, E., Kuzniewska, B., Kachamakova-Trojanowska, N., Barcikowska, M., Kuznicki, J., & Wojda, U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.017 · Cited by 32
Sharma, V., Gilhotra, R., Dhingra, D., & Gilhotra, N. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11026fp · Cited by 31
Hochstrasser, T., Marksteiner, J., Defrancesco, M., Deisenhammer, E. A., Kemmler, G., & Humpel, C. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000330468 · Cited by 31
Magini, A., Polchi, A., Tozzi, A., Tancini, B., Tantucci, M., Urbanelli, L., Borsello, T., Calabresi, P., & Emiliani, C. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.11.001 · Cited by 31
Yates, S. C., Zafar, A., Rabai, E. M., Foxall, J. B., Nagy, S., Morrison, K. E., Clarke, C., Esiri, M. M., Christie, S., Smith, A. D., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0114050 · Cited by 31 · cited 2×
“However, the evidence remains inconclusive, as a number of studies have reported increased levels in the brains of AD patients compared to controls [192,193], while others have found no significant differences [194].”
BackgroundTARGETING AGING WITH METFORMIN (TAME)
Barzilai, N. R. (2017) · Innovation in Aging · doi:10.1093/geroni/igx004.2682 · Cited by 30
Esteras, N., Bartolomé, F., Alquézar, C., Antequera, D., Muñoz, Ú., Carro, E., & Martín‐Requero, Á. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08178.x · Cited by 30
Shankar, G. M., Antony, J., & Anto, R. J. (2015) · The Enzymes · doi:10.1016/bs.enz.2015.05.001 · Cited by 29
Hinterberger, M., Fischer, P., Huber, K., Krugluger, W., & Zehetmayer, S. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1721-z · Cited by 28 · cited 1×
“However, a large community-based longitudinal study reported no difference in the telomere length between incident pure AD patients and cognitively healthy individuals [249].”
BackgroundPolyphenols Suppress and Modulate Inflammation
Kim, J., Lee, K. W., & Lee, H. J. (2013) · Polyphenols in Human Health and Disease · doi:10.1016/b978-0-12-398456-2.00029-3 · Cited by 28
The progeroid gene BubR1 regulates axon myelination and motor function
Choi, C.-I., Yoo, K. H., Hussaini, S. M. Q., Jeon, B. T., Welby, J., Gan, H., Scarisbrick, I. A., Zhang, Z., Baker, D. J., van Deursen, J. M., et al. (2016) · Aging · doi:10.18632/aging.101032 · Cited by 26 · cited 1×
“In addition, BUBR1 insufficiency, which causes a state of accelerated senescence impairs adult OPC proliferation in vivo [170].”
Esteras, N., Alquézar, C., Bermejo-Pareja, F., Bialopiotrowicz, E., Wojda, U., & Martín-Requero, Á. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.014 · Cited by 25 · cited 1×
“Interesting are also the results from AD and tauopathy mouse models [195,196], as well as from studies of peripheral blood lymphocytes and monocytes of AD patients [197,198].”
ResultRizou, S. V., Evangelou, K., Myrianthopoulos, V., Mourouzis, I., Havaki, S., Athanasiou, A., Vasileiou, P. V. S., Margetis, A., Kotsinas, A., Kastrinakis, N. G., et al. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-8931-7_12 · Cited by 25
Self-citationFood-Borne Topoisomerase Inhibitors
Esselen, M., & Barth, S. W. (2014) · Advances in molecular toxicology · doi:10.1016/b978-0-444-63406-1.00004-0 · Cited by 21
Siddiqui, M. S., Francois, M., Hecker, J., Faunt, J., Fenech, M. F., & Leifert, W. R. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.03.001 · Cited by 20
Han, L., Schuringa, J. J., Mulder, A. B., & Vellenga, E. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0948-7 · Cited by 20
Polyphenolics Evoke Healing Responses: Clinical Evidence and Role of Predictive Biomarkers
Jaffe, R., & Mani, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813006-3.00029-5 · Cited by 19
Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions
Garland, W., Benezra, R., & Chaudhary, J. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00015-6 · Cited by 17
Li, W., Wang, Z., Liu, S., Hu, Y., Yin, M., & Yang, L. (2016) · Stem Cells International · doi:10.1155/2016/7419389 · Cited by 11
Karamita, M., Nicholas, R., Kokoti, L., Rizou, S., Mitsikostas, D. D., Gorgoulis, V., Probert, L., & Papadopoulos, D. (2018) · Neurology · doi:10.1212/wnl.90.15_supplement.p2.405 · Cited by 8
Self-citation
Research works printed but not linked: 2
- Ay M. Charli A. Jin H. Anantharam V. Kanthasamy A. Kanthasamy A.G. Quercetin Nutraceuticals Gupta R.C. Academic Press Boston, MA, USA 2016 447 452
- Schnekenburger M. Diederich M. Nutritional Epigenetic Regulators in the Field of Cancer: New Avenues for Chemopreventive Approaches Epigenetic Cancer Therapy Gray S.G. Academic Press Boston, MA, USA 2015 393 425
Cited by
Role of p53 in the Regulation of Cellular Senescence
Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F., & Giordano, A. (2020) · Biomolecules · doi:10.3390/biom10030420 · Cited by 639
“This form of senescence is also known as stress-induced premature senescence (SIPS) and has broad implications in health and diseases [8,9].”
BackgroundHou, Y., Wei, Y., Lautrup, S., Yang, B., Wang, Y., Cordonnier, S., Mattson, M. P., Croteau, D. L., & Bohr, V. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011226118 · Cited by 530
“Several studies have provided strong evidence that genomic DNA damage leads to neuroinflammation, which can promote cellular senescence, and recent findings suggest that cell senescence occurs in glial cells in AD (40).”
BackgroundSex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
“IL-1β, IL-6, TGF-β, and TNF-α levels are elevated in AD brain tissue, as well as in AD patients’ CSF and serum (143).”
BackgroundOrr, M., Gonzales, M., Garbarino, V., Kautz, T., Palavicini, J., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J., Zare, H., Xu, P., et al. (2023) · doi:10.21203/rs.3.rs-2809973/v1 · Cited by 319
Metadata
- Authors
- Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Laboratory of Histology & Embryology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, Goudi, 115-27 Athens, Greece
- Corresponding author
- Gorgoulis, Vassilis G.
- Papadopoulos, Dimitrios
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-09-27
- Volume
- 19
- Issue
- 10
- Pages
- 2937
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6213570
- OpenAlex
- W2892390537
- Cited by
- 448
- References
- 385
- Citations by year
- 2026: 46 · 2025: 63 · 2024: 90 · 2023: 63 · 2022: 57 · 2021: 58 · 2020: 47 · 2019: 23 · 2018: 1
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Multiple Sclerosis Society (207495)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cellular senescence, aging, neurodegenerative diseases, senescence markers, lipofuscin, neurons, glial cells, Alzheimer's disease, Parkinson's disease, multiple sclerosis, senolytics, age-related diseases
- MeSH terms
- Aging, Animals, Humans, Cellular Senescence, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.